Managing Asthma with Controller Medications

Tiffany Budzinski, FNP-BC
Friday April 01, 2016
Asthma is a major health concern in the United States due to poor disease control. An estimated 23 million Americans have asthma, of whom 12 million experience an asthma exacerbation annually.1 Many patients with asthma are not being prescribed or actively taking a long-term controller medication, even though they are needed to manage asthma effectively and prevent exacerbations. Promoting the use of long-term controller medications as part of a patient’s management plan is key to managing this disease.
 
Current Shortfalls in Asthma Control
Lack of health care access, insufficient education, medication side effects, poor provider management, and lack of patient follow-up are the main reasons for the inadequate use of long-term controller medications. Lack of asthma control leads to an increased number of asthma exacerbations, which account for an estimated 1.8 million emergency room visits each year in the United States.2 Astonishing study results suggest that only 35.4% of the current asthma population uses a long-term controller for prevention of asthma exacerbations.1 In order to decrease the occurrence of asthma exacerbations and improve disease control, practitioners should become more familiar with long-term controller medications.

 

Long-Term Controller Medications for Asthma Management
The goal of asthma disease management is to control the patient’s asthma in order to decrease the number of exacerbations. Guides are available to assist practitioners in classifying asthma severity in patients aged 12 years and older (Table 13) and those younger than 12 years (Table 24). Using these guides as a foundation, a practitioner can use the stepwise approach to manage a patient’s asthma efficiently with selected long-term controller medications (Figure 15).
 


According to asthma guidelines from the National Heart, Lung, and Blood Institute (NHLBI), the new focus in monitoring asthma control is based on distinguishing between asthma severity and asthma control:
  • Asthma severity is defined as the “intrinsic intensity of the disease process.”4 Practitioners should evaluate asthma severity before initiating therapy.
  • Asthma control is defined as the “degree to which the manifestations of asthma…are minimized by therapeutic interventions and the goals of therapy are met.”4
Practitioners should then assess and monitor asthma control in order to adjust therapy based on the stepwise approach.
 
Within severity and control, the NHLBI focuses on 2 key domains: impairment and risk4:
  • Impairment is the “frequency and intensity of symptoms and functional limitations the patient is experiencing currently or had recently experienced.”
  • Risk is the “likelihood of either asthma exacerbations, progressive decline in lung function (or, for children, reduced lung growth), or risk of adverse effects from medication.”
 Based on symptom severity and control, including the domains of risk and impairment, a practitioner can either step up or step down when adjusting a patient’s daily long-term controller medication. This updated stepwise approach now includes age-specific guidelines (ages 0-4, 5-11, and 12+) to aid with a more focused treatment plan. Several classes of medication are included in the stepwise approach used to manage asthma control.
 
Inhaled Corticosteroids
Inhaled corticosteroids (ICSs) are the mainstay long-term medication for asthma control. Results of recent studies have shown that consistent use of ICSs will improve asthma symptoms more so than with any other long-term controller medication available for patients of any age.2 ICSs work by inhibiting inflammatory cytokines, thereby decreasing inflammation.6 This prevents and reduces airway swelling and reduces mucus in the lungs.7 Experts advise that ICSs are the first-line choice for controlling asthma because they decrease the number of asthma exacerbations, symptom frequency, and oral steroid use.2 Examples of ICSs include beclomethasone (QVAR), budesonide (Pulmicort), ciclesonide (Alvesco), flunisolide (Aerospan), fluticasone (Flovent), and mometasone furoate (Asmanex Twisthaler).8  The only ICS that is classified as pregnancy category B is budesonide.6 ICSs can be used long term as a safe and effective treatment for persistent asthma in patients of all ages.5
 
Leukotriene Receptor Antagonists
Leukotrienes are chemicals in the body that are released when a patient breathes in an allergen such as pollen. When leukotrienes are released into the body, swelling in the lungs and vasoconstriction of the airway can occur, potentially precipitating asthma symptoms.6 Blocking the leukotriene response terminates this reaction in the body. The 2 available leukotriene receptor antagonists are montelukast (Singular) and zafirlukast (Accolate). Montelukast is given once a day and can be given to children older than 12 months. Zafirlukast is given twice daily and can be given to children older than 7 years.2 Both are rated as pregnancy category B and are suitable for managing mild persistent asthma. Leukotriene receptor antagonists have a high rate of compliance because of their ease of use, and they also provide great control of asthma symptoms.2
 
Long-Acting Beta2-Agonists
Long-acting beta2-agonists (LABAs) include salmeterol (Serevent) and formoterol (Foradil). These medications are bronchodilators that selectively stimulate the beta2 adrenergic receptors, allowing the airways to vasodilate by relaxing the smooth muscles around them.7 Because LABAs are specific to beta2 adrenergic receptors, associated rates of tremor and tachycardia are low.2 LABAs should never be used as monotherapy for asthma control. As a result of increased asthma exacerbations and a rise in related deaths when LABAs were used alone, the FDA reviewed these medications and determined that they should be used only as part of combination therapy with an ICS.2 LABAs now require a black-box warning and are categorized as pregnancy class C. Pregnant patients should be advised by their practitioner about whether the benefit of taking a LABA outweighs the risk. LABAs should be considered for combination therapy when ICSs alone are not improving asthma symptoms.
 
Cromolyn Sodium
Cromolyn sodium is an inhaled nonsteroidal medication that stabilizes mast cells to prevent the airways from swelling when they come in contact with an asthma trigger.6,7 Although cromolyn sodium is used as an alternative medication option for asthma control, it is not an ideal medication. Newer medications are available that can better control asthma.
 
Immunomodulators
Omalizumab (Xolair) is an immunomodulator medication that is used as additive therapy for patients aged 12 years and older who have severe persistent asthma and demonstrated immediate hypersensitivity to inhaled allergens.2 It prevents binding of immunoglobulin E to mast cells and basophils, thereby inhibiting the body from reacting to allergic triggers.6 Omalizumab is administered as a subcutaneous injection every 2 to 4 weeks. At a cost of approximately $1048 for a single injection, however, the medication is expensive.6 In addition, it is advised that this medication be administered and monitored by an asthma specialist because of the black-box warning regarding the high risk for anaphylaxis.
 
Methylxanthines
Theophylline is a methylxanthine that is used as an alternative medication in patients with asthma, most effectively in combination with an ICS. Theophylline serum levels need to be monitored in patients taking this methylxanthine because toxicity can occur.2 Although theophylline is still used in some clinical situations, it is no longer the preferred asthma control treatment because patients do not often comply with monitoring serum theophylline levels. Newer, more effective medications are available.
 
Combination Therapy
Combination therapy in patients with asthma consists of an ICS combined with an LABA. Examples include budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair), and mometasone/formoterol (Dulera).6 Combination therapy is convenient for patients because it decreases the need for 2 separate inhalers. It is also safer for patients because the medications are already combined, decreasing potential side effects and lowering the incidence of black-box warning side effects with LABAs. Results from various studies have shown outstanding asthma control with combination therapy for moderate persistent asthma in patients aged 12 years and older.2
 
Oral Steroids
Oral steroid treatment is recommended not only for moderate to severe asthma exacerbations, but also for step 6 in the stepwise approach to asthma management (Figure 15). Dosing for oral steroid treatment is 1­ mg/kg/day to 2 mg/kg/day for 3 to 10 days in children, or 40 mg/kg/day to 60 mg/day in 1 or 2 divided doses for 5 to 10 days in adults. Tapering is not necessary because of the short course of treatment.2
 


Current Issue

The Educated Patient

Bethany Rettberg, NPC
Practitioners should get a detailed medical history and conduct a thorough physical to treat sinus infections.
Jennifer L. Hofmann, MS, PA-C
Providing them with advice can improve control of the disease and reduce hospitalizations, morbidity, and unscheduled health care visits.
Emily C. Hayes, PharmD Candidate
Colds, coughs, and a relentless influx of sick patients in retail health clinics keep the health care providers who work there very busy.
Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2019
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.